Yahoo
NasdaqGM - Nasdaq Real Time Price USD

ARS Pharmaceuticals, Inc. (SPRY)

3.0500 -0.3300 (-9.76%)
At close: November 2 at 4:00:00 PM EST
2.9913 -0.0587 (-1.92%)
After hours: November 2 at 4:55:55 PM EST
Trade SPRY on Coinbase
SPRY Q3 2026 earnings call
November 5, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for SPRY
  • Previous Close 3.3800
  • Open 3.4000
  • Bid 3.8900 x 200
  • Ask 6.7200 x 200
  • Day's Range 2.9100 - 3.4789
  • 52 Week Range 2.9100 - 13.1500
  • Volume 2,128,820
  • Avg. Volume 1,650,675
  • Market Cap (intraday) 303.314M
  • Beta (5Y Monthly) 1.16
  • PE Ratio (TTM) --
  • EPS (TTM) -1.9600
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 24.33
  • Motley Fool Rating Bearish

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

ars-pharma.com

195

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SPRY
73.82%
S&P 500 (^GSPC)
10.17%

1-Year Return

SPRY
65.96%
S&P 500 (^GSPC)
10.25%

3-Year Return

SPRY
16.44%
S&P 500 (^GSPC)
74.66%

5-Year Return

SPRY
66.15%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 33.66M
Earnings -62.34M
Profit Margin -185.21%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-60M
-40M
-20M
0
20M
-260.0%
-240.0%
-220.0%
-200.0%
-180.0%
-160.0%

Analyst Insights

View More

Analyst Price Targets

15.00
24.33 Average
3.0500 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Leerink Partners
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 24 -> 18

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -184.24%

  • Return on Assets (ttm)

    -48.02%

  • Return on Equity (ttm)

    -210.35%

  • Revenue (ttm)

    116.93M

  • Net Income Avi to Common (ttm)

    -215.43M

  • Diluted EPS (ttm)

    -1.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    143.84M

  • Total Debt/Equity (mrq)

    1,371.51%

  • Levered Free Cash Flow (ttm)

    -117.7M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: